Healthcare / Medical DevicesNasdaqGM
$19.12
+1.92 (+11.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-108.3M · quality 25.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-131.9%
↓Gross Margin
53.8%
↑Debt/Equity
2.86
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
+58.8%
FCF CAGR
—
FCF margin
-10.7%
FCF / Net income
0.53x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.01B · net income $-204.7M · FCF $-108.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $1.01B | $1.01B | $940.2M | $747.7M | $801.2M | $702.8M | $498.8M | $362.3M | $183.9M | $107.6M | $84.2M | $72.8M | $49.7M | $29.0M | $2.5M |
| Net Income | $-204.7M | $-204.7M | $-96.0M | $-222.6M | $-94.6M | $15.6M | $-34.4M | $-24.8M | $-122.6M | $-73.0M | $-83.4M | $-72.4M | $-79.5M | $-63.1M | $-33.0M |
| EBITDA | $-176.6M | $-176.6M | $-69.8M | $-196.5M | $-74.2M | $36.5M | $2.5M | $-10.7M | $-38.8M | $-56.1M | $-72.6M | $-64.2M | $-71.3M | $-46.3M | $-31.0M |
| EPS | -3.04 | -3.04 | -1.47 | -3.43 | -1.47 | 0.24 | -0.56 | -0.42 | — | — | — | — | — | — | — |
| Gross Margin | 53.8% | 53.8% | 52.1% | 49.2% | 51.5% | 53.5% | 52.2% | 53.6% | 48.9% | 41.0% | 28.0% | 36.5% | 30.7% | 21.3% | -54.5% |
| Operating Margin | -16.5% | -16.5% | -10.5% | -31.2% | -11.6% | 3.2% | -1.6% | -4.6% | -24.3% | -58.5% | -92.6% | -94.7% | -152.2% | -170.4% | -1335.3% |
| Net Margin | -20.2% | -20.2% | -10.2% | -29.8% | -11.8% | 2.2% | -6.9% | -6.8% | -66.7% | -67.9% | -99.0% | -99.4% | -159.9% | -217.7% | -1333.9% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 2.86 | 2.86 | 1.80 | 1.33 | 0.95 | — | — | — | — | -2.84 | -13.68 | 0.48 | 0.55 | — | — |
| Current Ratio | 3.58 | 3.58 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-108.3M | $-108.3M | $5.0M | $-128.1M | $16.4M | $97.2M | $-2.7M | $22.4M | $-11.3M | $-71.9M | $-70.1M | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -131.9% | -131.9% | -36.5% | -71.0% | -21.5% | 3.6% | -9.4% | -12.7% | -93.4% | 250.6% | 1407.9% | -114.1% | -145.7% | -54.6% | 31.1% |
| Valuation | |||||||||||||||
| P/B | 8.29 | 8.29 | 9.16 | 5.76 | 6.72 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 7.9% | 7.9% | 25.7% | -6.7% | — | 40.9% | 37.7% | 97.0% | 70.9% | 27.7% | 15.6% | 46.5% | 71.4% | 1072.0% | — |
| EPS Growth | -106.8% | -106.8% | 57.1% | -133.3% | — | 142.9% | -33.3% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.47 → -3.04
Residual
-3.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.